ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Cetirizine (ophthalmic): Drug information

Cetirizine (ophthalmic): Drug information
(For additional information see "Cetirizine (ophthalmic): Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Zerviate
Pharmacologic Category
  • Histamine H1 Antagonist;
  • Histamine H1 Antagonist, Second Generation;
  • Piperazine Derivative
Dosing: Adult
Allergic conjunctivitis

Allergic conjunctivitis: Ophthalmic: Instill 1 drop in affected eye(s) twice daily (~8 hours apart).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric
Allergic conjunctivitis

Allergic conjunctivitis: Ophthalmic: Children ≥2 years and Adolescents: Refer to adult dosing.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Local: Local pain (instillation site)

Ophthalmic: Decreased visual acuity, ocular hyperemia

Contraindications

There are no contraindications listed in the manufacturer's labeling.

Warnings/Precautions

Special populations:

• Contact lens wearers: Contains benzalkonium chloride, which may be absorbed by contact lenses; remove lenses prior to administration and wait 10 minutes before reinserting. Not for the treatment of contact lens irritation; do not wear contact lenses if eyes are red.

Other warnings/precautions:

• Appropriate use: For topical ophthalmic use only. To avoid eye injury and contamination, do not touch dropper tip of the bottle or single-use container to eyelids, surrounding area, or any surface.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Ophthalmic, as hydrochloride [strength expressed as base]:

Zerviate: 0.24% (30 ea) [contains benzalkonium chloride, edetate (edta) disodium, polysorbate 80]

Generic Equivalent Available: US

No

Pricing: US

Solution (Zerviate Ophthalmic)

0.24% (per each): $9.16

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

For topical ophthalmic use only. Use single-use containers immediately after opening; single-use containers can be used to dose both eyes. Wash hands before use. Do not touch dropper tip to eyelids, surrounding areas, or any surface. Remove contact lenses prior to administration. After instilling drops, wait ≥10 minutes before inserting contact lenses. Do not wear contacts lenses if eyes are red. Discard single-use container and remaining contents immediately after use.

Administration: Pediatric

Ophthalmic: For topical ophthalmic use only. Wash hands before use. Do not touch dropper tip to eyelids, surrounding areas, or any surface. Remove contact lenses prior to administration. After instilling drops, wait at least 10 minutes before inserting contact lenses. Do not wear contacts lenses if eyes are red.

Use: Labeled Indications

Allergic conjunctivitis: Treatment of ocular itching associated with allergic conjunctivitis.

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Pregnancy Considerations

The amount of cetirizine absorbed systemically following ophthalmic administration is significantly less than when administered orally. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease potential exposure to the fetus (Samples 1988).

Refer to the Cetirizine (Systemic) monograph for additional information.

Breastfeeding Considerations

It is not known if cetirizine is present in breast milk following ophthalmic administration. When administered orally, cetirizine enters breast milk. The amount of cetirizine absorbed systemically following ophthalmic administration is significantly less than when administered orally. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Refer to the Cetirizine (Systemic) monograph for additional information.

Mechanism of Action

Selective histamine H1-receptor antagonist for topical ophthalmic use.

Pharmacokinetics (Adult Data Unless Noted)

Half-life elimination: ~8 hours

  1. Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. Am J Ophthalmol. 1988;106(5):616-623. [PubMed 2903673]
  2. Zerviate (cetirizine) [prescribing information]. Fort Worth, TX: Eyevance Pharmaceuticals, LLC; June 2020.
Topic 113445 Version 39.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟